SRTA Stock Analysis: Strata Critical Medical | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 468m USD | 12M Return: 20.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.55M
Qual. Beats: 1
Rev. Trend: 75.0%
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Strata Critical Medical, Inc. (NASDAQ: SRTA) is a U.S. provider of time-critical logistics and medical services focused on the organ transplant and surgical support markets. The company operates through two reporting segments: Logistics and Clinical, reflecting its combination of transport operations and hands-on medical procedure services.
The Logistics segment includes air and ground transportation for human organs, transplant teams, and related medical materials, along with organ placement coordination. The Clinical segment covers organ recovery procedures, normothermic regional perfusion, and organ preservation, as well as ancillary services such as cardiac perfusion, blood management and autotransfusion, extracorporeal membrane oxygenation (ECMO) support, perfusion staffing, and equipment rentals. Organ and tissue transport is a niche, time-sensitive field where logistics providers must coordinate flights, ground transport, and hospital hand-offs within strict viability windows.
The company was founded in 2014 and is headquartered in New York, New York. It was previously known as Blade Air Mobility, Inc. and adopted the Strata Critical Medical name in August 2025, marking a strategic shift away from its prior urban air mobility business toward a healthcare-focused model.
- U.S. organ transplant volumes drive Logistics segment revenue
- Clinical segment expansion in perfusion and ECMO services lifts margins
- Reimbursement rate changes pressure medical services profitability
| Net Income: 47.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA -7.62 > 1.0 |
| NWC/Revenue: 40.59% < 20% (prev 51.86%; Δ -11.28% < -1%) |
| CFO/TA -0.12 > 3% & CFO -39.7m > Net Income 47.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.2m) vs 12m ago 12.86% < -2% |
| Gross Margin: 21.68% > 18% (prev 24.16%; Δ -2.47% > 0.5%) |
| Asset Turnover: 87.96% > 50% (prev 100.4%; Δ -12.42% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.32 (Total Current Assets 124.1m - Total Current Liabilities 20.9m) / Total Assets 327.6m |
| B: -0.44 (Retained Earnings -143.4m / Total Assets 327.6m) |
| C: -0.08 (EBIT TTM -22.8m / Avg Total Assets 289.1m) |
| D: 6.82 (Book Value of Equity 285.7m / Total Liabilities 41.9m) |
| Altman-Z'' = 7.27 = AAA |
| DSRI: 1.77 (Receivables 39.6m/22.1m, Revenue 254.3m/251.5m) |
| GMI: 1.11 (GM 24.16% / 21.68%) |
| AQI: 2.14 (AQ_t 0.49 / AQ_t-1 0.23) |
| SGI: 1.01 (Revenue 254.3m / 251.5m) |
| TATA: 0.26 (NI 47.0m - CFO -39.7m) / TA 327.6m) |
| Beneish M = -1.58 (Cap -4..+1) = CCC |
As of July 11, 2026, the stock is trading at USD 5.11 with a total of 922,674 shares traded. Over the past week, the price has changed by -5.55%, over one month by -6.75%, over three months by +26.49% and over the past year by +20.24%.
Current recommended Stop Loss: 4.50 (which is 11.9% or 2.3 ATR below the current price).
Strata Critical Medical has no consensus analysts rating.
P/E Forward = 138.8889
P/S = 2.0479
P/B = 1.6368
Revenue TTM = 254.3m USD
EBIT TTM = -22.8m USD
EBITDA TTM = -13.2m USD
Long Term Debt = 3.48m USD (estimated: total debt 4.47m - short term 987k)
Short Term Debt = 987k USD (from shortTermDebt, last quarter)
Debt = 4.47m USD (from shortLongTermDebtTotal, last quarter) (leases 4.47m already included)
Net Debt = -54.3m USD (calculated: Debt 4.47m - CCE 58.8m)
Enterprise Value = 413.8m USD (468.1m + Debt 4.47m - CCE 58.8m)
Interest Coverage Ratio = unknown (Ebit TTM -22.8m / Interest Expense TTM 0.0)
EV/FCF = -7.81x (Enterprise Value 413.8m / FCF TTM -53.0m)
FCF Yield = -12.81% (FCF TTM -53.0m / Enterprise Value 413.8m)
FCF Margin = -20.84% (FCF TTM -53.0m / Revenue TTM 254.3m)
Net Margin = 18.48% (Net Income TTM 47.0m / Revenue TTM 254.3m)
Gross Margin = 21.68% ((Revenue TTM 254.3m - Cost of Revenue TTM 199.1m) / Revenue TTM)
Gross Margin QoQ = 20.95% (prev 17.47%)
Tobins Q-Ratio = 1.26 (Enterprise Value 413.8m / Total Assets 327.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.47m)
Taxrate = 10.32% (248k / 2.40m)
NOPAT = -20.4m (EBIT -22.8m * (1 - 10.32%)) [loss with tax shield]
Current Ratio = 5.93 (Total Current Assets 124.1m / Total Current Liabilities 20.9m)
Debt / Equity = 0.02 (Debt 4.47m / totalStockholderEquity, last quarter 285.7m)
Debt / EBITDA = 4.11 (negative EBITDA) (Net Debt -54.3m / EBITDA -13.2m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -54.3m / FCF TTM -53.0m)
Total Stockholder Equity = 267.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.26% (Net Income 47.0m / Total Assets 327.6m)
RoE = 17.55% (Net Income TTM 47.0m / Total Stockholder Equity 267.7m)
RoCE = -8.39% (EBIT -22.8m / Capital Employed (Equity 267.7m + L.T.Debt 3.48m))
RoIC = -6.92% (negative operating profit) (NOPAT -20.4m / Invested Capital 294.9m)
WACC = 13.01% (E(468.1m)/V(472.6m) * Re(13.13%) + D(4.47m)/V(472.6m) * Rd(0.0%) * (1-Tc(0.10)))
Discount Rate = 13.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 8.75%
[DCF] Fair Price = unknown (Cash Flow -53.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.10 | # QB: 1
Revenue Correlation: 74.96 | Revenue CAGR: 7.20% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.03 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.14 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+54.2% | GrowthRev=+39.1%
EPS next Year (2027-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+75.0% | GrowthRev=+10.7%
[Analyst] Revisions Ratio: -17% (up=1, down=2)